Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built.

NEW YORK, August 18, 2026 — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today welcomed President Donald J. Trump’s latest announcement supporting the accelerated development of ibogaine as a potential medical treatment in the United States.
President Trump announced today that the University of Miami has provided the U.S. Federal Government with its original 1994 ibogaine Investigational New Drug (“IND”) application, which he said could help accelerate ibogaine’s development as a medical treatment in the United States.
The President also highlighted progress since his April Executive Order, including HHS research funding, HHS-VA collaboration, FDA guidance and efforts to expand Right to Try access for veterans.
President Trump concluded his statement with a call for additional companies and institutions to participate in the effort.
“This is what Psyence BioMed was built for,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “The President has made clear that the United States wants serious companies and institutions to step forward and help advance ibogaine. We are ready to answer that call.”
Aufrichtig and Psyence BioMed Chief Financial Officer Warwick Corden-Lloyd are currently in Texas meeting with stakeholders and other leaders in the emerging U.S. ibogaine ecosystem to discuss recent progress, the evolving regulatory and policy environment, and opportunities to advance the responsible clinical development of ibogaine in the United States.
“The timing of the President’s announcement is particularly meaningful as Warwick and I are here in Texas engaging directly with stakeholders who are working to turn this growing momentum into tangible progress,” Aufrichtig added. “There is a real sense of urgency around this work, particularly for veterans, and Psyence BioMed intends to be an active participant in determining what comes next.”
Psyence BioMed has been building a vertically integrated pharmaceutical platform designed to support the regulated clinical development of ibogaine. The Company holds an ownership interest in PsyLabs, a pharmaceutical manufacturing operation producing GMP-compliant psychedelic active pharmaceutical ingredients, including ibogaine hydrochloride. Through PsyLabs, Psyence BioMed has access to pharmaceutical-grade manufacturing capabilities and an existing inventory of GMP-compliant ibogaine hydrochloride to support clinical development.
PsyLabs is a core component of Psyence BioMed’s ibogaine strategy, providing manufacturing infrastructure and pharmaceutical expertise as the United States moves toward establishing regulated pathways for ibogaine research and development.
“The conversation around ibogaine has changed dramatically,” Aufrichtig continued. “This is no longer a discussion taking place at the margins of medicine. The White House, HHS, the VA, FDA, researchers and states are increasingly asking how ibogaine can be studied safely, responsibly and at the standards expected of a pharmaceutical medicine. Those are exactly the questions we have been preparing to help answer.”
Psyence BioMed believes the Administration’s latest action reinforces the growing momentum toward regulated ibogaine development in the United States and the need for pharmaceutical-grade manufacturing, rigorous clinical development and close regulatory engagement.
Learn more about the company at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708

Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com

About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics and the manufacturing of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

About PsyLabs
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
PsyLabs operates from an ISO 22000 and GMP-compliant facility, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics. www.psylabs.life